Roughly ten million people die from cancer every year, making it the cause of around one-in-six deaths and one of the most significant global health problems. Besides the overlooked explosion in cancers following the COVID-19 jabs, the world has seen a massive 75 percent rise in the number of cancer deaths between 1990 and 2019, with 20 million new cancers and 9.7 million deaths in 2022, according to the World Health Organization. Mind you, these unacceptable numbers exist despite the fact that in 2021, U.S. taxpayers forked out $6.4 billion to the National Cancer Institute (NCI) to fund its incessant quest to research cancer. And if that weren’t enough to ignite and solidify distrust in the lucrative cancer industry, the American Cancer Society covertly admits that cancer treatments actually increase the likelihood of a “second cancer.”

First, and of course, “second” cancers are unbelievably profitable for doctors, hospitals, and Big Pharma—but more often than not, devastating to the cancer patient. A novel anti-cancer drug in the United States costs a cancer patient more than $100,000 per year of treatment for unsatisfactory results. Indeed, most cancer drugs offer only modest benefits, with one study putting the median benefit at 2.1 extra months of life, with most survivors likely being incredibly sick. It is heartbreaking.

Anyone who has watched a loved one go through cancer treatment will attest to the fact doctors soft-pedal the devastation that most often results from cancer treatment. And rest assured, there is no mention of more affordable, more holistic alternative treatments like Ivermectin and its anti-cancer mechanisms. Highlighting the shady dealings between doctors and Big Pharma, in 2019, STAT reported that 85 percent of the experts who wrote widely used cancer guidelines received payments averaging over $10,000 from Big Pharma. The corruption goes a step further, as these guidelines mandate that Medicare pay for off-label use of cancer drugs, which further lines the pockets of those involved. Research shows that physicians consistently paid by Big Pharma are more likely to prescribe that company’s drugs. Undoubtedly, the unspoken bonus at the end is the conceivable emergence of the “second cancer.”

In a testament to its crusade to keep the medical industry in business, the ACS has known about “Second Cancers Caused by Cancer Treatment” since at least 2010 and has successfully kept it out of the cancer conversation for decades. The ACS has confessed that “Radiation therapy was recognized as a potential cause of cancer many years ago.” They also concede that most types of leukemia, including acute myelogenous leukemia (AML), chronic myelogenous leukemia (CML), and acute lymphoblastic leukemia (ALL), can all be caused by radiation. Most cancers caused by radiation therapy develop within just a few years of being irradiated, with the second cancer peaking at five to nine years following exposure.

Likewise, chemotherapy drugs (and targeted therapy drugs) have been directly linked to various kinds of second cancers, with the most common being myelodysplastic syndrome (MDS) and AML. Similarly, ALL has also been linked to these cancer drugs. Without proper tracking, making it impossible to provide accurate data, it is estimated that at a minimum, radiation and chemotherapy cancer drugs cause at least 40,000 “second cancer” cases each year in the U.S.

Breaking that down, in 2015, each year around 13,000 people were diagnosed with MDS, 6,000 with ALL, and, roughly another 20,000 diagnosed annually with AML. Over half of those cases ended in death. Yet again, it is difficult to determine how many people die from second cancers resulting from cancer drugs because most deaths are recorded as being from cancer, not the treatment. Precisely like the hype behind COVID-19, cancer fear is fueled by a wicked and clandestine game of smoke and mirrors.

Make no mistake: this all-encompassing game to destroy your health keeps the medical-industrial complex afloat—the last thing it wants is for you to be well or well-informed. The mission to deceive is so much so that the International Agency for Research on Cancer (IARC), the WHO’s self-appointed global body on cancer research, makes no mention of “second cancers” anywhere on its extensive website. And the shady group has been around since 1965! Instead, the IARC promotes fear of cancer, with early detection and treatment the answer, declaring:

“One in five people worldwide develop cancer during their lifetime. Prevention of cancer has become one of the most significant public health challenges of the 21st century. It has a critical role to play in the fight against cancer. Based on current scientific evidence, at least 40% of all cancer cases could be prevented with effective primary prevention measures, and further mortality can be reduced through early detection of tumours.”

Meanwhile, in a January 17, 2024 publication titled “Cancer statistics, 2024,”—noting that delays in diagnosis and treatment of cancer occurred in 2020 because of the fear of COVID-19 exposure—the ACS altogether ignored “second cancers.” Nothing to see here, folks, move on … despite having an entire section on its website discussing “second cancers,” which was last revised on February 1, 2020. Moreover, the ACS piece also skimmed right over the deadly gene-damaging jabs as it sought to project cancer cases and deaths in 2024.

The manipulation is mind-boggling. With, of course, a heavy focus on the significance of DEI in dealing with cancers, one might wonder if perhaps the mission behind the report is to offer a vague platform to explain the barrage of cancer gripping society—especially the younger population—after it was coercively jabbed with the experimental COVID-19 shots. In that case, it stands to reason that “second cancers” be kept out of the conversation altogether. It is a game played all too well, with Big Pharma, Big Tech, and the corrupt mainstream media in place as key players. Instead, remarking that “national progress will require increased investment in cancer prevention and access to equitable treatment,” as certain cancers are sure to rise, the abstract predicted:

“In 2024, 2,001,140 new cancer cases and 611,720 cancer deaths are projected to occur in the United States. Cancer mortality continued to decline through 2021, averting over 4 million deaths since 1991 because of reductions in smoking, earlier detection for some cancers, and improved treatment options in both the adjuvant and metastatic settings.

However, these gains are threatened by increasing incidence for 6 of the top 10 cancers. Incidence rates increased during 2015–2019 by 0.6%–1% annually for breast, pancreas, and uterine corpus cancers and by 2%–3% annually for prostate, liver (female), kidney, and human papillomavirus-associated oral cancers and for melanoma.

Incidence rates also increased by 1%–2% annually for cervical (ages 30–44 years) and colorectal cancers (ages <55 years) in young adults. Colorectal cancer was the fourth-leading cause of cancer death in both men and women younger than 50 years in the late 1990s but is now first in men and second in women.”